T-sema3A

T-sema3A is a recombinant, engineered, truncated form of the endogenous immunoregulatory protein semaphorin-3A (sema3A). Originally discovered and designed at the Technion - Israel Institute of Technology, it was developed by the spinout company Symbol Therapeutics. T-sema3A is engineered to selectively bind and signal through the immune-regulatory CD72 receptor on B and T lymphocytes while lacking the C-terminal domain required to bind neuropilin-1 (NRP-1), thereby avoiding the unwanted endothelial and neuronal effects associated with wild-type sema3A. Upon binding CD72, T-sema3A down-regulates STAT-4 and HDAC-1 phosphorylation and up-regulates PKC-theta and p38-MAPK phosphorylation. This signaling cascade promotes the expression of anti-inflammatory regulatory cytokines (such as IL-10 and TGF-beta) and suppresses pro-inflammatory cytokines (such as IL-6, IFN-gamma, and IL-17A), aiming to restore self-tolerance and immune homeostasis in autoimmune and inflammatory diseases. Symbol Therapeutics ceased operations and entered liquidation in November 2025, leading to the discontinuation of the program.

Other names

modified sema3Amodified truncated sema3Atruncated sema3Atruncated semaphorin-3Atruncated-semaphorin3Atruncated-semaphorin-3Atruncated-semaphorin 3A